TransCode Therapeutics (RNAZ) Stock: Buy, Sell, or Hold?
RNAZ - TransCode Therapeutics, Inc. Common Stock
$1.66
-0.02 (-1.19%)
âŧ
5d:
-4.05%
30d:
-6.21%
90d:
-77.1%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 13, 2026
21d
Get Alerted When RNAZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: RNAZ is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: RNAZ is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: RNAZ is currently trading at $1.66, which is considered slightly low relative to its 30-day fair value range of $1.63 to $1.76.
Technical Outlook: Technically, RNAZ is in a strong downtrend. Immediate support is located at $1.60, while resistance sits at $1.95.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.00 (+502.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNAZ is in a strong downtrend. Immediate support is located at $1.60, while resistance sits at $1.95.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.00 (+502.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.63 -
$1.76
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 502.4% below Wall St target ($10.00)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.63 -
$1.76
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.60
Resistance Level
$1.95
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.19
Wall Street Target
$10.00
(+502.4%)
Share & Embed Analysis
Last updated: October 22, 2026 8:54 AM ET
Data refreshes hourly during market hours. Next update: 9:54 AM
Data refreshes hourly during market hours. Next update: 9:54 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 66 BUY |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$686 | 59 HOLD |
|
CGON
CG Oncology, Inc. CommonâĻ |
STRONG BUY
15 analysts |
$91 | 73 BUY |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 63 BUY |
